Cost-effectiveness of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) testing and isolation strategies in nursing homes

被引:2
|
作者
Bartsch, Sarah M. [1 ,2 ,3 ]
Weatherwax, Colleen [1 ,2 ,3 ]
Martinez, Marie F. [1 ,2 ,3 ]
Chin, Kevin L. [1 ,2 ,3 ]
Wasserman, Michael R. [4 ,5 ]
Singh, Raveena D. [6 ]
Heneghan, Jessie L. [1 ,2 ,3 ]
Gussin, Gabrielle M. [6 ]
Scannell, Sheryl A. [1 ,2 ,3 ]
White, Cameron [1 ,2 ,3 ]
Leff, Bruce [7 ]
Huang, Susan S. [6 ]
Lee, Bruce Y. [1 ,2 ,3 ,8 ]
机构
[1] CUNY, Ctr Adv Technol & Commun Hlth CATCH, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10027 USA
[2] CUNY, Publ Hlth Informat Computat & Operat Res PHICOR, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10027 USA
[3] CUNY, Artificial Intelligence Modeling Informat Nutr Gui, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10027 USA
[4] Los Angeles Jewish Home, Reseda, CA USA
[5] Calif Assoc Long Term Care Med, Santa Clarita, CA USA
[6] Univ Calif Irvine, Div Infect Dis, Sch Med, Irvine, CA USA
[7] Johns Hopkins Univ, Ctr Transformat Geriatr Res, Div Geriatr Med, Sch Med, Baltimore, MD USA
[8] CUNY, New York City Pandem Response Inst PRI, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10027 USA
基金
美国医疗保健研究与质量局;
关键词
COVID-19; EFFICACY; OUTCOMES;
D O I
10.1017/ice.2024.9
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective: Nursing home residents may be particularly vulnerable to coronavirus disease 2019 (COVID-19). Therefore, a question is when and how often nursing homes should test staff for COVID-19 and how this may change as severe acute respiratory coronavirus virus 2 (SARS-CoV-2) evolves.Design: We developed an agent-based model representing a typical nursing home, COVID-19 spread, and its health and economic outcomes to determine the clinical and economic value of various screening and isolation strategies and how it may change under various circumstances.Results: Under winter 2023-2024 SARS-CoV-2 omicron variant conditions, symptom-based antigen testing averted 4.5 COVID-19 cases compared to no testing, saving $191 in direct medical costs. Testing implementation costs far outweighed these savings, resulting in net costs of $990 from the Centers for Medicare & Medicaid Services perspective, $1,545 from the third-party payer perspective, and $57,155 from the societal perspective. Testing did not return sufficient positive health effects to make it cost-effective [$50,000 per quality-adjusted life-year (QALY) threshold], but it exceeded this threshold in >= 59% of simulation trials. Testing remained cost-ineffective when routinely testing staff and varying face mask compliance, vaccine efficacy, and booster coverage. However, all antigen testing strategies became cost-effective (<=$31,906 per QALY) or cost saving (saving <=$18,372) when the severe outcome risk was >= 3 times higher than that of current omicron variants.Conclusions: SARS-CoV-2 testing costs outweighed benefits under winter 2023-2024 conditions; however, testing became cost-effective with increasingly severe clinical outcomes. Cost-effectiveness can change as the epidemic evolves because it depends on clinical severity and other intervention use. Thus, nursing home administrators and policy makers should monitor and evaluate viral virulence and other interventions over time.
引用
收藏
页码:754 / 761
页数:8
相关论文
共 50 条
  • [31] Is There an Association Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Streptococcus pneumoniae?
    Howard, Leigh M.
    CLINICAL INFECTIOUS DISEASES, 2021, 72 (05) : E76 - E78
  • [32] Emerging Biosensors to Detect Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Review
    Lim, Wei Yin
    Lan, Boon Leong
    Ramakrishnan, Narayanan
    BIOSENSORS-BASEL, 2021, 11 (11):
  • [33] A review of metallic nanostructures against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
    Istuti Saraswat
    Sarmistha Saha
    Anuja Mishra
    Toxicology and Environmental Health Sciences, 2023, 15 : 315 - 324
  • [34] Ergebnisse der präoperativen SARS-CoV-2-Testung („severe acute respiratory syndrome coronavirus 2“) in der CoronaviruspandemieResults of preoperative SARS-CoV-2 testing in the coronavirus pandemic
    M.-C. Rassweiler-Seyfried
    T. Miethke
    K.-P. Becker
    F. Siegel
    Der Urologe, 2021, 60 (3): : 331 - 336
  • [35] Routine surveillance of asymptomatic healthcare personnel for severe acute respiratory coronavirus virus 2 (SARS-CoV-2): Not a prevention strategy
    Shenoy, Erica S.
    Weber, David J.
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2021, 42 (05) : 592 - 597
  • [36] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and glial cells: Insights and perspectives
    Vargas, Gabriele
    Geraldo, Luiz Henrique Medeiros
    Salomao, Natalia Gedeao
    Paes, Marciano Viana
    Lima, Flavia Regina Souza
    Gomes, Flavia Carvalho Alcantara
    BRAIN BEHAVIOR & IMMUNITY-HEALTH, 2020, 7
  • [37] Transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to animals: an updated review
    Salajegheh Tazerji, Sina
    Magalhaes Duarte, Phelipe
    Rahimi, Parastoo
    Shahabinejad, Fatemeh
    Dhakal, Santosh
    Singh Malik, Yashpal
    Shehata, Awad A.
    Lama, Juan
    Klein, Jorn
    Safdar, Muhammad
    Rahman, Md. Tanvir
    Filipiak, Krzysztof J.
    Rodriguez-Morales, Alfonso J.
    Sobur, Md. Abdus
    Kabir, Farrokhreza
    Vazir, Bita
    Mboera, Leonard
    Caporale, Marco
    Islam, Md. Saiful
    Amuasi, John H.
    Gharieb, Rasha
    Roncada, Paola
    Musaad, Sahar
    Tilocca, Bruno
    Koohi, Mohammad Kazem
    Taghipour, Ali
    Sait, Ahmet
    Subbaram, Kannan
    Jahandideh, Alireza
    Mortazavi, Pejman
    Abedini, Mohammad Amin
    Hokey, David A.
    Hogan, Unarose
    Shaheen, Mohamed N. F.
    Elaswad, Ahmed
    Elhaig, Mahmoud M.
    Fawzy, Mohamed
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)
  • [38] Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a Dog in Connecticut in February 2021
    Lee, Dong-Hun
    Helal, Zeinab H.
    Kim, Junwon
    Hunt, Amelia
    Barbieri, Alyza
    Tocco, Natalie
    Frasca, Salvatore, Jr.
    Kerr, Kirklyn
    Hyeon, Ji-Yeon
    Chung, David H.
    Risatti, Guillermo
    VIRUSES-BASEL, 2021, 13 (11):
  • [39] Evaluation of the diagnosis and treatment options for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
    Kouhpayeh, Hamidreza
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2022, 11 (08) : 4219 - 4227
  • [40] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated
    Wambier, Carlos Gustavo
    Goren, Andy
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (01) : 308 - 309